{"tm":1686890071,"s":"KYMR","news":[{"t":"Kymera Therapeutics to Participate in Upcoming June Investor Conference","dt":"Jun-01-23 07:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-participate-upcoming-june-110000131.html"},{"t":"Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253","dt":"May-19-23 07:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-doses-first-patient-110000852.html"},{"t":"Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript","dt":"May-09-23 03:15PM","a":"Insider Monkey","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-inc-nasdaq-kymr-191540463.html"},{"t":"Some Shareholders Feeling Restless Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) P\/S Ratio","dt":"Apr-19-23 11:11AM","a":"Simply Wall St.","u":"https:\/\/finance.yahoo.com\/news\/shareholders-feeling-restless-over-kymera-151135680.html"},{"t":"12 Small-Cap Stocks With Insider Buying","dt":"Mar-09-23 03:00PM","a":"Insider Monkey","u":"https:\/\/finance.yahoo.com\/news\/12-small-cap-stocks-insider-200008015.html"},{"t":"Q4 2022 Kymera Therapeutics Inc Earnings Call","dt":"Feb-24-23 02:53AM","a":"Thomson Reuters StreetEvents","u":"https:\/\/finance.yahoo.com\/news\/q4-2022-kymera-therapeutics-inc-075305260.html"},{"t":"Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23","dt":"Feb-01-23 07:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-report-fourth-quarter-120000639.html"},{"t":"Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?","dt":"Jan-23-23 04:14AM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/revance-therapeutics-inc-rvnc-soars-091409172.html"},{"t":"All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy","dt":"Jan-09-23 12:00PM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/know-kymera-therapeutics-inc-kymr-170005650.html"},{"t":"7 Perfect Presents to Gift Your 2023 Stock Portfolio","dt":"Dec-21-22 04:57PM","a":"InvestorPlace","u":"https:\/\/finance.yahoo.com\/news\/7-perfect-presents-gift-2023-215702678.html"},{"t":"Small Biotech Kymera Just Snagged Sanofi's Interest  Here's Why","dt":"Dec-14-22 04:09PM","a":"Investor's Business Daily","u":"https:\/\/finance.yahoo.com\/m\/b635a92b-1d56-3422-8a99-ced455b6fb10\/small-biotech-kymera-just.html"},{"t":"Kymera's stock rallies as it plans to move treatment into Phase 2 studies next year","dt":"07:57AM","a":"MarketWatch","u":"https:\/\/finance.yahoo.com\/m\/1cf16c1f-e085-3870-a691-26ccb43f1253\/kymera%27s-stock-rallies-as-it.html"},{"t":"Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting","dt":"Dec-11-22 10:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-presents-preclinical-data-150000508.html"},{"t":"These Analysts Think Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Sales Are Under Threat","dt":"Nov-05-22 08:33AM","a":"Simply Wall St.","u":"https:\/\/finance.yahoo.com\/news\/analysts-think-kymera-therapeutics-inc-123353992.html"},{"t":"Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors","dt":"07:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-appoints-biopharmaceutical-leader-110000904.html"},{"t":"Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline","dt":"Oct-13-22 04:15PM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-hold-investor-webcast-201500642.html"},{"t":"CyberOptics and Mirum Pharmaceuticals Stock See Action From Activist Investors","dt":"Aug-26-22 06:20PM","a":"Barrons.com","u":"https:\/\/www.barrons.com\/articles\/cyberoptics-and-mirum-pharmaceuticals-stock-see-action-from-activist-investors-51661552400?siteid=yhoof2"},{"t":"ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox","dt":"Aug-11-22 10:01AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/prokidney-strengthens-board-directors-appointments-140100367.html"},{"t":"Will Humanigen Inc. (HGEN) Report Negative Q2 Earnings? What You Should Know","dt":"Aug-04-22 10:00AM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/humanigen-inc-hgen-report-negative-140002328.html"},{"t":"Kymera Therapeutics to Report Second Quarter 2022 Results on August 9","dt":"Jul-27-22 07:30AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-report-second-quarter-113000971.html"},{"t":"Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413","dt":"Jun-15-22 07:00AM","a":"PR Newswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-doses-first-patients-110000370.html"},{"t":"3 Biotech Stocks to Buy Before They Boom","dt":"06:15AM","a":"InvestorPlace","u":"https:\/\/finance.yahoo.com\/news\/3-biotech-stocks-buy-boom-101524489.html"},{"t":"Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation","dt":"May-05-22 08:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-share-novel-preclinical-120000797.html"},{"t":"Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates","dt":"08:15AM","a":"Zacks","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-inc-kymr-reports-121512782.html"},{"t":"Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022","dt":"Apr-08-22 01:02PM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-presents-preclinical-data-170200803.html"},{"t":"Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update","dt":"07:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-announces-fourth-quarter-120000209.html"},{"t":"We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn","dt":"Feb-07-22 07:55AM","a":"Simply Wall St.","u":"https:\/\/finance.yahoo.com\/news\/were-not-worried-kymera-therapeutics-125519026.html"},{"t":"Is Kymera Therapeutics, Inc. (KYMR) A Good Stock To Buy?","dt":"Jan-12-22 12:42PM","a":"Insider Monkey","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-inc-kymr-good-174215783.html"},{"t":"Biotech: Interest in vaccine stocks will probably wane, strategist says","dt":"Dec-22-21 11:11AM","a":"Yahoo Finance Video","u":"https:\/\/finance.yahoo.com\/video\/biotech-interest-vaccine-stocks-probably-161121740.html"},{"t":"Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations","dt":"Dec-06-21 08:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-strengthens-leadership-team-130000363.html"},{"t":"Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting","dt":"Nov-12-21 07:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-presents-preclinical-data-120000029.html"},{"t":"Kymera Therapeutics (NASDAQ:KYMR) shareholder returns have been respectable, earning 48% in 1 year","dt":"Nov-08-21 07:35AM","a":"Simply Wall St.","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-nasdaq-kymr-shareholder-123513369.html"},{"t":"Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences","dt":"Nov-01-21 08:00AM","a":"GlobeNewswire","u":"https:\/\/finance.yahoo.com\/news\/kymera-therapeutics-participate-upcoming-fourth-120000313.html"}]}